Anti-angiogenic drug is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) and Fudan University (1). Registered phases: Phase 2 and Observational. Conditions studied include Metastatic Triple-negative Breast Cancer; Gastric Cancer; Second-line Treatment.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. (ClinicalTrials.gov ↗) Metastatic Triple-negative Breast Cancer |
Phase 2 | Recruiting |
| NCT07389876 | Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma (ClinicalTrials.gov ↗) Gastric Cancer, Second-line Treatment |
Observational | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Triple-negative Breast Cancer | 1 |
| Gastric Cancer | 1 |
| Second-line Treatment | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Fudan University | 1 |
| Register | Anti-angiogenic drug trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anti-angiogenic drug works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-angiogenic drug (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.